Oncology/Hematology Market Research Reports & Industry Analysis
Oncology/Hematology Industry Research & Market Reports
-
Uterine Cancer Therapeutics and Diagnostics
... Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Endometrial Carcinomas, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.0 Billion ... Read More
-
Basal Cell Carcinoma Treatment
... 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Surgery, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$7.6 Billion by the end ... Read More
-
Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC)
... are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending ... Read More
-
Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2025
... including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global ... Read More
-
Advanced Melanoma - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Advanced Melanoma: Understanding Advanced Melanoma: ... Read More
-
Oncology Based In-Vivo CRO
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by the ... Read More
-
Cancer Therapies
... CAGR of 10.4% over the analysis period 2024-2030. Blood Cancer, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$119.2 Billion by the end of the analysis ... Read More
-
Bladder Cancer Therapeutics
... at a CAGR of 4.4% over the analysis period 2024-2030. Transitional Cell Bladder Cancer, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$114.6 Million by the ... Read More
-
Cancer Cachexia
... CAGR of 5.7% over the analysis period 2024-2030. Progestogens, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.5 Billion ... Read More
-
Cancer Biomarkers
... CAGR of 16.9% over the analysis period 2024-2030. Protein Biomarkers, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$42.9 Billion by the end of the analysis ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Genomics in Cancer Care
... 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$25.0 Billion by the end ... Read More
-
Interventional Oncology Devices
... at a CAGR of 6.4% over the analysis period 2024-2030. Embolization Devices, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.4 Billion by the end of ... Read More
-
Breast Biopsy Devices
... at a CAGR of 5.6% over the analysis period 2024-2030. Biopsy Guidance Systems, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$983.4 Million by the end ... Read More
-
Breast Cancer Therapeutics
... at a CAGR of 12.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of ... Read More
-
Cancer Gene Therapy
... at a CAGR of 20.9% over the analysis period 2024-2030. Oncolytic Virotherapy, one of the segments analyzed in the report, is expected to record a 21.7% CAGR and reach US$4.3 Billion by the end of ... Read More
-
Pancreatic Cancer Drugs
... at a CAGR of 4.6% over the analysis period 2024-2030. Exocrine, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$3.2 Billion by the end of the ... Read More
-
Cancer / Tumor Profiling
... 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Immunoassays, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$6.7 Billion by the end ... Read More
-
Tumor / Cancer Markers
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 10.4% CAGR The Tumor / Cancer Markers market ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
-
In-Vitro Colorectal Cancer Screening Tests
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More
-
Cancer Supportive Care Drugs Global Market Report 2025
... care drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly ... Read More
-
Multiple Myeloma - Market Insight, Epidemiology, and Market Forecast - 2034
... incident cases, label expansion and penetration of current therapies in earlier lines, high adoption of newer therapies mainly CAR-T cell therapies and anti-BCMA, rich emerging pipeline, and expected increase in investment in the R&D activities ... Read More
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$12.1 Billion by the end of ... Read More
Research Assistance
